TORONTO, ON, CANADA / OCTOBER 11, 2022 - Ripple Therapeutics Corporation, a clinical stage ophthalmic therapeutics company, announced today the signing of an exclusive Licensing Agreement for the Chinese rights to their lead product, IBE-814, with CS Pharmaceuticals (“CSP”), a British headquartered multinational company focused on the development and commercialization of rare disease and ophthalmology products in China.

Ripple’s Epidel® technology platform is founded on a discovery that drugs can be engineered into controlled release pharmaceuticals without the use of polymers or excipients. The proprietary prodrugs have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants and micro/nanoparticles) or as coatings on medical devices. The implants and coatings undergo surface erosion to give zero order drug release kinetics and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest.

Ripple’s first program, IBE-814 IVT, is an intravitreal dexamethasone prodrug implant targeting diabetic macular edema (DME) and retinal vein occlusion (RVO). RIPPLE-1, a Phase II trial evaluating IBE-814 IVT, in currently underway in Australia, New Zealand, Hong Kong and Canada with 52 patients treated to date.

Ripple previously announced, in December 2020, a licensing agreement for North America and Europe with Théa Open Innovation (“TOI”) a wholly owned subsidiary of Laboratoires Théa, the leading independent ophthalmology pharmaceutical company in Europe. 

“We’re excited about the clinical results with IBE-814 IVT and the signing of this licensing agreement for China is testament to the commercial potential of this product”, remarked Tom Reeves, President & CEO of Ripple Therapeutics. “We’ve been impressed by the CSP management team and their deep understanding of and experience with the clinical, regulatory and commercial requirements in China. We look forward to working with them to bring this product to market to provide Chinese patients with a safe and effective treatment for DME and RVO.”

“Securing the Chinese commercial rights to IBE-814 marks another milestone for CSP, as we continue to expand our portfolio of innovative products in China.  Our team of dedicated market access, commercial, medical and compliance experts, is excited at the prospect of working with Ripple to develop and launch this important product,” commented Darren Mercer, CS Pharmaceuticals’ Chief Executive. “Completing this transaction further validates our unique business model, focused on bringing innovative rare disease and ophthalmology medicines to Chinese patients, to address the significant unmet medical needs in this rapidly growing market.”

About Ripple Therapeutics

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The core feature of Ripple’s Epidel™ technology is the ability to engineer sustained-release pharmaceuticals with zero-order release kinetics without the use of polymers or excipients. Ripple’s novel therapeutics provide for better outcomes for patients, easier management of care for physicians and lower costs for payors.  Ripple has a full product pipeline in development. www.rippletherapeutics.com

About CS Pharmaceuticals

CS Pharmaceuticals is a British multinational company focused on licensing Chinese commercialization rights to Western rare disease and ophthalmology medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast growing market. With its dedicated commercialization platform, CSP is rapidly becoming a ‘go-to’ trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China. www.cspharmaceuticals.com

Media Contact

Julie Fotheringham, V.P. Marketing, People & Culture

M: 416-951-7988 E: jfotheringham@rippletherapeutics.com